When was S&E bio founded?

S&E bio was founded in 2019 and raised its 1st funding round 3 years after it was founded.

Where is S&E bio located?

S&E bio is headquartered in Seoul, South Korea.

Is S&E bio a funded company?

S&E bio is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Dec 30, 2022.

When was the latest funding round of S&E bio?

S&E bio's latest funding was a $***** Series A round on Dec 30, 2022, with participation from 4 investors.

Where does S&E bio rank among its competitors?

S&E bio ranks 10th amongst 79 active competitors, of which 28 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Remedium Bio, which secured $10M in Aug, 2026.

Who are the top competitors of S&E bio?

S&E bio's top competitors include Secretome Therapeutics, Mesoblast and RoosterBio. Among them, Remedium Bio secured the most recent funding round in August, 2026.

S&E bio - 2026 Company Profile, Team, Funding & Competitors

S&E bio is a series A company based in Seoul (South Korea), founded in 2019. It operates as a Developer of cell therapies for neurological disorders. S&E bio has raised $7.34M in funding from investors like KB Investment, Korea Investment Holdings and Company K Partners. The company has 79 active competitors, including 28 funded and 14 that have exited. Its top competitors include companies like Secretome Therapeutics, Mesoblast and RoosterBio.

Company Details

Developer of cell therapies for neurological disorders. The company is developing mesenchymal stem cell-derived extracellular vesicles therapeutics for the treatment of acute stroke, moyamoya disease, chronic stroke, dementia, cognitive disorder, and others.

Website: snebio.com
Phone Number: +82 **********

Key Metrics

Founded Year

2019

Location

Seoul, South Korea

Stage

Series A

Total Funding

$7.34M in 1 round

Latest Funding Round

Series A, Dec 30, 2022, $*****

Investors

KB Investment & 3 more

Ranked

10^th among 79 active competitors

Similar Companies

Secretome Therapeutics & 109 more

View S&E bio's full profile

S&E bio has raised a total funding of $7.34M over 1 round. Its latest funding round was a Series A round on Dec 30, 2022 for $*****. 4 investors participated in its latest round. S&E bio has 4 institutional investors.

Here is the list of recent funding rounds of S&E bio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 30, 2022	1648508	Series A	5220073	8522100	8026369	9554062

Access funding benchmarks and valuations. Sign up today!

View details of S&E bio's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of S&E bio include Secretome Therapeutics, Mesoblast and RoosterBio. Here is the list of Top 10 competitors of S&E bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Secretome Therapeutics 2018, Dallas (United States), Series A	Developer of cell-based therapies for multiple diseases	$52.2M	RA Capital Management, Parent Project Muscular Dystrophy ... & 2 others	61/100
2nd	Mesoblast 2004, Melbourne (Australia), Public	Biotherapeutics derived from proprietary adult stem cell-based technologies	-	Celgene, Hercules Capital & 8 others	60/100
3rd	RoosterBio 2012, Frederick (United States), Series B	Developer of human mesenchymal stem cells and extracellular vesicles	$38.4M	Planetary Technologies, Dynamk Capital & 4 others	57/100
4th	SCM Lifescience 2014, Incheon (South Korea), Public	Stem cell therapeutics and related services	$4.8M	Yozma, Synergy IB investment & 6 others	56/100
5th	Remedium Bio 2020, Needham (United States), Series A	Developer of gene therapies for a broad range of diseases	$15M	LifeSpan Vision Ventures, hkxcapital.com ... & 10 others	56/100
6th	Bioxodes 2013, Marche en Famenne (Belgium), Series A	Developer of novel peptide therapies for prevention of thrombosis	$45.4M	SFPI, Newton Biocapital & 3 others	55/100
7th	BrainStorm Cell 2000, Petah Tikva (Israel), Public	Developer ofstem cell therapies for the treatment of neurodegenerative diseases such as ALS, MS, PD	-	ALS Association, Iconic Private Equity Partners ... & 6 others	54/100
8th	Stempeutics 2006, Bengaluru (India), Series A	Stem-cell-based products for osteoarthritis and buerger's disease	$47.3M	MNI Ventures, Max Medisupport & 6 others	52/100
9th	NuvOx Therapeutics 2008, Tucson (United States), Funding Raised	Developer of an oxygen therapeutic drug designed to reverse tissue hypoxia	-	Pasadena Angels, Military Health & 1 others	49/100
10th	S&E bio 2019, Seoul (South Korea), Series A	Developer of cell therapies for neurological disorders	$7.34M	LSK investment, Company K Partners & 2 others	49/100